Yangbai Sun1, Jiangyu Cai1, Fengfeng Li1, Shen Liu1, Hongjiang Ruan1, Cunyi Fan2. 1. Department of Orthopaedics, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China. 2. Department of Orthopaedics, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China. Electronic address: fancunyi888@hotmail.com.
Abstract
BACKGROUND: Heterotopic ossification (HO) recurrence after joint surgery is always a disturbing problem for patients and surgeons. Our study was performed to assess the efficacy and safety of celecoxib in preventing the recurrence of HO after open arthrolysis for post-traumatic elbow stiffness. METHODS: We retrospectively studied 152 patients with stiff elbows caused by post-traumatic HO. After surgery, 77 patients received celecoxib (200 mg once daily) for 28 days, whereas 75 did not. Radiographic evaluation was performed at 3, 6, and 9 months postoperatively. Univariate and multivariate analyses were performed to determine which factors affected HO recurrence. RESULTS: HO was both more common and more severe in the no-celecoxib group than in the celecoxib group at 3, 6, and 9 months after surgery. A significant difference was observed between the 2 groups in terms of postoperative extension (P = .030), flexion (P = .008), and pronation (P = .005); however, no significant difference in postoperative supination was noted (P = .622). Logistic regression analysis showed that taking celecoxib was the protective factor for HO recurrence, whereas overweight (body mass index > 25) and male gender were the risk factors. CONCLUSIONS: A short course of celecoxib aids in the prevention of HO recurrence after open arthrolysis for elbow stiffness in adults and could be an effective and safe option.
BACKGROUND: Heterotopic ossification (HO) recurrence after joint surgery is always a disturbing problem for patients and surgeons. Our study was performed to assess the efficacy and safety of celecoxib in preventing the recurrence of HO after open arthrolysis for post-traumatic elbow stiffness. METHODS: We retrospectively studied 152 patients with stiff elbows caused by post-traumatic HO. After surgery, 77 patients received celecoxib (200 mg once daily) for 28 days, whereas 75 did not. Radiographic evaluation was performed at 3, 6, and 9 months postoperatively. Univariate and multivariate analyses were performed to determine which factors affected HO recurrence. RESULTS: HO was both more common and more severe in the no-celecoxib group than in the celecoxib group at 3, 6, and 9 months after surgery. A significant difference was observed between the 2 groups in terms of postoperative extension (P = .030), flexion (P = .008), and pronation (P = .005); however, no significant difference in postoperative supination was noted (P = .622). Logistic regression analysis showed that taking celecoxib was the protective factor for HO recurrence, whereas overweight (body mass index > 25) and male gender were the risk factors. CONCLUSIONS: A short course of celecoxib aids in the prevention of HO recurrence after open arthrolysis for elbow stiffness in adults and could be an effective and safe option.
Authors: Shailesh Agarwal; Shawn J Loder; Christopher Breuler; John Li; David Cholok; Cameron Brownley; Jonathan Peterson; Hsiao H Hsieh; James Drake; Kavitha Ranganathan; Yashar S Niknafs; Wenzhong Xiao; Shuli Li; Ravindra Kumar; Ronald Tompkins; Michael T Longaker; Thomas A Davis; Paul B Yu; Yuji Mishina; Benjamin Levi Journal: Mol Ther Date: 2017-07-15 Impact factor: 11.454
Authors: Shawn J Loder; Shailesh Agarwal; Michael T Chung; David Cholok; Charles Hwang; Noelle Visser; Kaetlin Vasquez; Michael Sorkin; Joe Habbouche; Hsiao H Sung; Joshua Peterson; David Fireman; Kavitha Ranganathan; Christopher Breuler; Caitlin Priest; John Li; Xue Bai; Shuli Li; Paul S Cederna; Benjamin Levi Journal: Am J Pathol Date: 2018-08-22 Impact factor: 4.307